The role of adjuvant hormonal treatment after surgery for localized high-risk prostate cancer: Results of a matched multiinstitutional analysis

Abstract

Introduction. To assess the role of adjuvant androgen deprivation therapy (ADT) in high-risk prostate cancer patients (PCa) after surgery. Materials and Methods. The analysis case matched 172 high-risk PCa patients with positive section margins or non-organ confined disease and negative lymph nodes to receive adjuvant ADT (group 1, n=86) or no adjuvant ADT (group 2, n=86). Results. Only 11.6 of the patients died, 2.3 PCa related. Estimated 510-year clinical progression-free survival was 96.9 (94.3) for group 1 and 73.7 (67.0) for group 2, respectively. Subgroup analysis identified men with T2/T3a tumors at low-risk and T3b margins positive disease at higher risk for progression. Conclusion. Patients with T2/T3a tumors are at low-risk for metastatic disease and cancer-related death and do not need adjuvant ADT. We identified men with T3b margin positive disease at highest risk for clinical progression. These patients benefit from immediate adjuvant ADT. Copyright © 2012 Maria Schubert et al.